SUMMARY
DelveInsight’s,“ Leishmaniasis (Kala-Azar)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Leishmaniasis (Kala-Azar). This report provides information on the therapeutic development based on the Leishmaniasis (Kala-Azar) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Leishmaniasis (Kala-Azar) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Leishmaniasis (Kala-Azar)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Table of Contents
- Leishmaniasis (Kala-Azar) Overview
- Leishmaniasis (Kala-Azar) Pipeline Therapeutics
- Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies
- Leishmaniasis (Kala-Azar) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Leishmaniasis (Kala-Azar) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Leishmaniasis (Kala-Azar) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) - Discontinued Products
- Leishmaniasis (Kala-Azar) - Dormant Products
- Companies Involved in Therapeutics Development for Leishmaniasis (Kala-Azar)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Leishmaniasis (Kala-Azar), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Leishmaniasis (Kala-Azar) Assessment by Monotherapy Products
- Leishmaniasis (Kala-Azar) Assessment by Combination Products
- Leishmaniasis (Kala-Azar) Assessment by Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Stage and Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) Assessment by Stage and Molecule Type
- Leishmaniasis (Kala-Azar) Therapeutics - Discontinued Products
- Leishmaniasis (Kala-Azar) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Leishmaniasis (Kala-Azar), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Leishmaniasis (Kala-Azar) Assessment by Monotherapy Products
- Leishmaniasis (Kala-Azar) Assessment by Combination Products
- Leishmaniasis (Kala-Azar) Assessment by Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Stage and Route of Administration
- Leishmaniasis (Kala-Azar) Assessment by Molecule Type
- Leishmaniasis (Kala-Azar) Assessment by Stage and Molecule Type

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

9 Companies

Company Profiles

Cision AB

Sweden

Staples UK Retail Ltd.

United Kingdom

AstraZeneca PLC

United Kingdom

SYNTHES Inc.

Switzerland

Biosense Webster Inc.

United States

Sangamo BioSciences Inc.

United States

Synthes Inc.

United States

Johnson and Johnson

United States

Staples Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.